Keywords: Impax, Generics, Welcol, Patent challenge, Daiichi Sankyo, Genzyme
Impax Labs sued by Daiichi Sankyo and Genzyme after challenging Welchol patent in USA
Article | 18 January 2010
US generic drugmaker Impax Laboratories confirmed that it has initiated a challenge to patents listed by Japanese drug firm Daiichi Sankyo in connection with its cholesterol-lowering product Welchol (colesevelam HCl) tablets, 625mg, including one that US biotech major Genzyme inherited when it acquired GelTex Pharmaceuticals in 2000. The patents are claimed to expire in 2014 and 2015.
Impax filed its Abbreviated New Drug Application containing a paragraph IV certification for a generic version of Welchol with the US Food & Drug Administration. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
